Circulation, Vol 76, 254-258, Copyright © 1987 by American Heart Association
FG Dunn, HO Ventura, FH Messerli, I Kobrin and ED Frohlich
Regression of left ventricular hypertrophy occurs with a number of
antihypertensive drugs, but the time course of this regression has not been
defined clearly. We obtained echocardiograms at baseline and serially (on
seven occasions) during a 1 year treatment period with the beta-adrenergic
receptor inhibitor atenolol in 12 patients with previously untreated
essential hypertension. To ensure control of blood pressure in all patients
throughout the study, it was necessary to add a thiazide diuretic to the
therapy of five patients. Baseline blood pressure was 155/100 mm Hg and
fell to 136/84 mm Hg; there was a 20% reduction in heart rate. Posterior
and septal wall thicknesses were reduced from 1.16 +/- 0.03 to 1.06 +/-
0.02 cm (p less than .05) and from 1.28 +/- 0.07 to 1.18 +/- 0.06 cm (p
less than .05), respectively; this reduction became significant initially
at 4 weeks. Left ventricular mass decreased from 144 +/- 9 to 127 +/- 7
g/m2 (p less than .05) and this fall first became statistically significant
at 6 months. Significant reduction in electrocardiographic voltages was
also seen at 6 months. Therefore, regression of left ventricular
hypertrophy with atenolol-induced blood pressure control occurred as early
as 4 weeks after starting therapy and was maintained thereafter without
apparent compromise of left ventricular systolic function.
ARTICLES
Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol
This article has been cited by other articles:
 |
|
 |
|
  M. Kingsbury, A. Mahnke, M. Turner, and D. Sheridan Recovery of coronary function and morphology during regression of left ventricular hypertrophy Cardiovasc Res, July 1, 2002; 55(1): 83 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mayet, B. Ariff, B. Wasan, N. Chapman, M. Shahi, N. R. Poulter, P. S. Sever, R. A. Foale, and S. A. McG. Thom Improvement in Midwall Myocardial Shortening With Regression of Left Ventricular Hypertrophy Hypertension, November 1, 2000; 36(5): 755 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Frohlich Risk Mechanisms in Hypertensive Heart Disease Hypertension, October 1, 1999; 34(4): 782 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goldstein {beta}-Blockers in Hypertensive and Coronary Heart Disease Arch Intern Med, June 24, 1996; 156(12): 1267 - 1276. [Abstract] [PDF]
|
|
|
|
 |
|
 E. D. Frohlich, D. Aristizabal, F. Soria, and F. H. Messerli Investigative Concerns in Demonstrating Reduced Risk from Reversing Left Ventricular Hypertrophy Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 17 - 22. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Lim, A. L. Barkan, and A. J. Buda Rapid Reduction of Left Ventricular Hypertrophy in Acromegaly after Suppression of Growth Hormone Hypersecretion Ann Intern Med, November 1, 1992; 117(9): 719 - 726. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Klein, R. Zweiker, B. Eber, J. Dusleag, H. Brussee, and B. Rotman Circadian Blood Pressure Pattern in Patients with Treated Hypertension and Left Ventricular Hypertrophy Angiology, May 1, 1991; 42(5): 379 - 386. [Abstract] [PDF]
|
|
|
|
 |
|
 R. E. Schmieder, J. K. Rockstroh, and F. H. Messerli Antihypertensive Therapy: To Stop or Not to Stop? JAMA, March 27, 1991; 265(12): 1566 - 1571. [Abstract] [PDF]
|
|
|
|
|
|
D. Levy, R. J. Garrison, D. D. Savage, W. B. Kannel, and W. P. Castelli Left Ventricular Mass and Incidence of Coronary Heart Disease in an Elderly Cohort: The Framingham Heart Study Ann Intern Med, January 15, 1989; 110(2): 101 - 107. [Abstract] [PDF]
|
|
|
|
 |
|
 ANTIHYPERTENSIVE THERAPY REDUCES HYPERTROPHY WITHIN 4 WEEKS Journal Watch (General), August 11, 1987; 1987(811): 4 - 4. [Full Text]
|
|